Nanobiotix ( (NBTX) ) has issued an announcement.
On April 10, 2025, Nanobiotix announced the acquisition of shares by individuals with managerial responsibilities, as per the EU Market Abuse Regulation. These transactions, which occurred on April 3, 4, and 8, 2025, involved the purchase of shares on Euronext Paris at varying prices and volumes. This disclosure is part of the company’s compliance with regulatory requirements, reflecting transparency in its operations and potentially impacting stakeholder perceptions.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix faces significant challenges with profitability and financial stability, reflected in its financial performance and valuation scores. Technical indicators suggest bearish momentum, further weighing on the stock. The neutral earnings call impact keeps the overall score stable but modest.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a company operating in the biotechnology industry, focusing on developing innovative nanomedicine products. Their primary products are designed to enhance the efficacy of cancer treatments, with a significant market focus on oncology therapies.
YTD Price Performance: 9.31%
Average Trading Volume: 12,767
Technical Sentiment Signal: Strong Buy
Current Market Cap: $149.4M
See more data about NBTX stock on TipRanks’ Stock Analysis page.